Pathology Doctors in Port Chester, NY Accepting Medicare

8 Pathology doctors found. Showing 1 - 8

Dr. Howard B Goldstein, M.D. Pathology - Dermatopathology Medicare: Not Enrolled in Medicare Practice Location: 100 Midland Ave, Port Chester, NY 10573 Phone: 914-636-0136    Fax: 914-636-5075

Dr. Naghmeh Yousefzadeh, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 100 Midland Ave, Port Chester, NY 10573 Phone: 914-934-5836    Fax: 914-934-9819

Dr. Alan J Halperin, MD Pathology - Dermatopathology Medicare: Not Enrolled in Medicare Practice Location: 100 Midland Ave, Port Chester, NY 10573 Phone: 800-942-3376    Fax: 914-934-9819

Dr. Damian P Dicostanzo, MD Pathology - Dermatopathology Medicare: Accepting Medicare Assignments Practice Location: 100 Midland Ave, Port Chester, NY 10573 Phone: 800-942-3376    Fax: 914-934-9819

Dr. Kenneth J Shulman, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 100 Midland Ave, Port Chester, NY 10573 Phone: 800-942-3376    Fax: 914-934-9819

Patrick S Brunhoeber, MD Pathology - Dermatopathology Medicare: Not Enrolled in Medicare Practice Location: 100 Midland Ave, Port Chester, NY 10573 Phone: 800-942-3376    Fax: 914-934-9819

Marie C Sicari, MD Pathology - Anatomic Pathology Medicare: Not Enrolled in Medicare Practice Location: 100 Midland Ave, Port Chester, NY 10573 Phone: 914-934-9739    Fax: 914-934-9819

Dr. Ekaterina Castano, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Medicare Enrolled Practice Location: 10 Pearl St Fl 4, Port Chester, NY 10573 Phone: 914-937-3300    Fax: 914-937-3322

News Archive

Patent for Aciphex ruled valid and enforceable

PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Federal Circuit Court of Appeals affirmed the judgments of the United States District Court for the Southern District of New York that the patent for Aciphex (rabeprazole sodium 20 mg tablets) is valid and enforceable.

Liver cancer time-bomb as up to 70% people with Hep C miss out on follow-up testing

Up to 70 per cent of Victorians with suspected hepatitis C may not have received follow-up testing, putting them at risk of chronic liver disease and even cancer, University of Melbourne researchers say.

Hepatitis C therapy peginterferon alfa-2b shows promise

The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).

Journals highlight issues related to hostile sexism and society's role in creative genius

Men who generally believe that women who challenge men's power are manipulative and subversive - so-called hostile sexism - carry over those antagonistic attitudes into their intimate relationships.

Read more Medical News

› Verified 5 days ago